Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Condoliase - Seikagaku Corporation

Drug Profile

Condoliase - Seikagaku Corporation

Alternative Names: C-ABC; ChABC; Chondroitin-sulfate-ABC endolyase; Chondroitinase ABC; HERNICORE; SI-6603

Latest Information Update: 16 Aug 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Seikagaku Corporation
  • Developer Kaken Pharmaceutical; Seikagaku Corporation
  • Class Chondroitin lyases
  • Mechanism of Action Chondroitin sulfate proteoglycan modulators; Glycosaminoglycan modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Intervertebral disc displacement

Most Recent Events

  • 01 Aug 2018 Launched for Intervertebral disc displacement in Japan (Intraspinal) - First global launch
  • 30 May 2018 Seikagaku Corporation initiates a phase III trial for Intervertebral disc displacement in USA (Intraspinal) (NCT03607838)
  • 22 May 2018 Seikagaku Corporation and Kaken Pharmaceutical plan to launch condoliase for Intervertebral disc displacement in Japan in August 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top